Motley Fool

10 Sep Stock Analysis

Cannabis could be an industry that takes the Oracle of Omaha’s portfolio to new highs.

10 Sep Stock Analysis

Decelerating growth has some investors spooked, but don’t miss out on the big picture.

10 Sep Stock Analysis

There are several healthcare companies in Berkshire Hathaway’s portfolio, but only one in its top 10 holdings.

10 Sep Stock Analysis

Catalysts are on the horizon for these bargain stocks.

10 Sep Stock Analysis

Johnson & Johnson’s Invega Hafyera was approved by the FDA as the first and only twice-yearly injectable treatment for…

10 Sep Stock Analysis

The U.S. launch of Alzheimer’s disease drug Aduhelm is off to a sluggish start.

09 Sep Stock Analysis

Aduhelm’s commercial launch isn’t off to a strong start.

09 Sep Stock Analysis

Whether the market is hot or not, these are some ways you can find good stocks to buy.

09 Sep Stock Analysis

Is it too late to buy shares of HubSpot and Sea Limited?

09 Sep Stock Analysis

These popular companies are seeing their shares move in the wrong direction.